Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Sponsor: Rutgers, The State University of New Jersey
Summary
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Official title: Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I/II Feasibility Study
Key Details
Gender
FEMALE
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-06
Completion Date
2029-06
Last Updated
2026-06-11
Healthy Volunteers
No
Conditions
Interventions
MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI guidance and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk.
Locations (1)
Rutgers Cancer Institut Jersey
New Brunswick, New Jersey, United States